Amazon Pharmacy and GoodRx both sell themselves as the easy discount route to a GLP-1, and on the evidence gathered for this article on 15 October 2026, neither of them is really setting the price. Both quote the drugmaker's own self-pay figure. The ladders match to the dollar. That makes the headline question, which one actually saves more, a narrower question than it looks, because the saving does not come from the logo on the checkout page. It comes from the access fee bolted on beside the medication, and from which of the two will show you a number before you hand over a prescription.
DoseTruth is a price-comparison publisher: it is not a pharmacy, not a telehealth provider, and it does not prescribe or dispense any medication. This article is for general information about prices and is not medical advice, and you should speak to a licensed clinician before starting, stopping, or changing any medication.
Every price below carries the date it was checked and the source it came from. Two prices in this comparison could not be obtained at all in this session, and rather than estimate them, this article says where the wall is and what it blocks. One of the figures that matters most to the annual total, the current GoodRx access fee, rests on conflicting reporting, and that is written up as conflicting rather than resolved.
Which route actually sets the price you pay?
The manufacturer sets it, and both Amazon Pharmacy and GoodRx are channels that display it. This is the single most important fact in the comparison and it is the one most likely to be missed, because a coupon site and a retailer both look like they are doing the discounting.
Novo Nordisk states the arrangement plainly in its own announcement. In a press release dated 29 April 2025, the company describes launching NovoCare Pharmacy to provide direct-to-patient home shipments of all dose strengths of Wegovy at a reduced cost, with telehealth organisations working through that pharmacy rather than pricing independently. The release names Hims and Hers, LifeMD, and Ro as collaborators and identifies CenterWell Pharmacy as the fulfilment party. The price is Novo Nordisk's. The partners are routes to it.
The same structure shows up in GoodRx's own newsroom, in the title of the release itself. On 5 January 2026 GoodRx announced that it now offers Novo Nordisk's cash price for the launch of the Wegovy pill, at $149 per month across more than 70,000 pharmacies. That is not the language of a negotiated discount. Reporting the same day in The American Journal of Managed Care described GoodRx as matching the Novo Nordisk price, with $149 for the 1.5 mg and 4 mg doses through 15 April 2026, then $199 for the 4 mg dose and $299 for the 9 mg and 25 mg doses.
The independent check comes from KFF. In a brief dated 24 February 2026 on the value of TrumpRx to customers, KFF notes that many of the self-pay discounted prices shown on TrumpRx are also available via direct-to-consumer options on the manufacturer's website, and that most of the TrumpRx coupons are also displayed on GoodRx. KFF also notes that archived GoodRx pages show prices available in 2025 or earlier were higher than those currently advertised. On GLP-1 medicines the mechanism has changed from a coupon applied to a retail price into a window onto a price the manufacturer already fixed.
What does Amazon Pharmacy charge for a GLP-1 today?
Amazon publishes floors, not a full price list, and those floors are identical to the manufacturer's published ladder. Amazon's own programme page, originally published 21 April 2026 and updated 15 September 2026, was retrieved on 15 October 2026. It gives cash-pay oral medication, covering Wegovy and Foundayo, starting at $149 per month, and cash-pay injectable medication, covering Wegovy, Zepbound, and the Zepbound KwikPen, starting at $199 per month. Insured patients may pay as little as $25 per month, and eligible Medicare patients are quoted $50 a month.
The clinical access fee sits outside those numbers. Amazon's page prices One Medical on-demand care at $39 for direct message care and $59 for video care, and states that the cost of medications is separate from the cost of the visit. No One Medical membership is required, and medications ship to all 50 states, with same-day delivery in nearly 3,100 cities and an intended expansion to about 4,500 by the end of 2026. The on-demand tier does not include prior-authorisation support.
| Item | Published figure | What it does not tell you |
|---|---|---|
| Oral, Wegovy pill and Foundayo, cash-pay | starting at $149 per month | the price of the 4 mg, 9 mg and 25 mg doses |
| Injectable, Wegovy, Zepbound, KwikPen, cash-pay | starting at $199 per month | which drug and dose the $199 applies to |
| With commercial insurance | as low as $25 per month | your own plan's copay or deductible |
| Eligible Medicare patients | $50 per month | the eligibility test |
| One Medical on-demand visit | $39 message, $59 video, per visit | how many visits a year you will need |
Two things about that table deserve naming. First, the floors moved inside six months. Pharmaceutical Executive, reporting on the programme launch on 22 April 2026, recorded injectable cash-pay starting at $299 per month and visit fees of $29 and $49. Amazon's September page shows $199 and $39 and $59. A floor advertised as a starting price is a moving object, which is the same trap covered in our piece on advertised price versus maintenance dose.
Second, the $199 injectable floor is not an Amazon invention. It is Novo Nordisk's introductory offer. The NovoCare Pharmacy self-pay page, checked live on 15 October 2026, shows the Wegovy pen at $199 per month for the first two months for new patients, flagged as a limited-time offer with pricing to be updated after 31 December 2026, then $349 per month for the 0.25 mg through 2.4 mg doses and $399 per month for Wegovy HD 7.2 mg. One month is defined as one box of four pens. The same page lists the Wegovy pill at $149 for 1.5 mg, $199 for 4 mg, and $299 for the 9 mg and 25 mg doses, with one month defined as one bottle of 30 tablets.
What does GoodRx charge for the same drug and dose?
The same manufacturer figures, on the available evidence, plus a monthly subscription whose current size this article could not confirm. GoodRx's price history on these drugs tracks Novo Nordisk's price history step for step.
| Date | GoodRx announcement | Manufacturer price at that date | Source type |
|---|---|---|---|
| 18 August 2025 | Ozempic and Wegovy pens for self-pay patients at $499 per month | $499 per month via NovoCare Pharmacy | company release, primary for its own price |
| 17 November 2025 | $39 per month weight-loss telemedicine subscription, introductory cash price of $199 per month for Ozempic and Wegovy | Novo cut direct-to-consumer price from $499 to $349, and launched a $199 introductory offer for the two lowest doses, first two months | company release title, plus business press |
| 5 January 2026 | Wegovy pill at $149 per month at more than 70,000 pharmacies, described as Novo Nordisk's cash price | $149 for 1.5 mg, rising to $199 for 4 mg after 15 April 2026, $299 for 9 mg and 25 mg | company release, plus clinical trade journal |
| 9 April 2026 | Foundayo at $149 per month and Zepbound KwikPen at $299 per month across more than 70,000 pharmacies | Lilly self-pay KwikPen starting at $299 for 2.5 mg | trade publication, not primary |
The Novo Nordisk side of that table is confirmed by business press at the time. CNBC reported on 17 November 2025 that Novo cut direct-to-consumer prices for Wegovy and Ozempic to $349 per month from $499, kept the highest Ozempic dose at $499, and launched a temporary introductory offer of $199 per month for the first two months on the two lowest doses, originally ending 31 March. Pharmaceutical Commerce, reporting on 18 November 2025, listed the channels carrying that introductory offer as wegovy.com and ozempic.com, NovoCare Pharmacy, and retail and telehealth partners including Costco, GoodRx, WeightWatchers, Ro, LifeMD and eMed. GoodRx appears there as one of Novo's distribution channels, in a list, alongside a warehouse club.
On the Lilly side, Pharmaceutical Executive reported on 1 December 2025 that Zepbound single-dose vials moved to $299 a month for 2.5 mg, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg doses through LillyDirect. The American Journal of Managed Care reported on 23 February 2026 that the FDA approved a four-dose single-patient-use KwikPen delivering a full month in one device, with self-pay pricing starting at $299 per month for the 2.5 mg dose. Lilly's own investor releases were unreachable in this session, which is noted again in the scoring table below. The refill-timing condition attached to Lilly's self-pay tiers is covered separately in our piece on the LillyDirect 45-day rule in real numbers.
Can you see either price before you commit?
No, and this is the clearest practical difference between the two routes, though not in the direction either company's marketing suggests. Neither price could be read off a public page in this session.
Amazon's main pharmacy page, retrieved on 15 October 2026, markets upfront and transparent pricing and offers a medication search box, but displays no drug price to a signed-out visitor. The price appears at checkout, after sign-in, against a prescription on file. Two plausible GLP-1 landing paths under the pharmacy domain returned 404. So Amazon's per-dose price for the Wegovy injection or for Zepbound is not publicly quotable. The $349 and $399 figures used for Amazon in the annual model below are taken from NovoCare's published ladder, not confirmed on Amazon's own site, and that inference is the weakest link in this comparison.
GoodRx was harder still. Requests to its Wegovy page returned HTTP 403, and a reader proxy returned a human-verification wall asking the visitor to press and hold to confirm they are not a bot. That was attempted with a standard browser user agent and through an intermediary, and neither worked. No live GoodRx coupon price for any GLP-1 was obtained in this session, so every GoodRx figure quoted here comes from a dated company announcement or trade report rather than from the site today.
So which one saves more over a year?
On the medication itself, neither, because the medication price is the same. The difference is entirely in the access fee, and there Amazon's pay-per-visit model is cheaper than a twelve-month subscription for anyone who needs only a few contacts a year.
| Cost component | Amazon Pharmacy route | GoodRx route |
|---|---|---|
| Months 1 and 2, introductory price | 2 at $199, total $398 | 2 at $199, total $398 |
| Months 3 to 12, standard price | 10 at $349, total $3,490 | 10 at $349, total $3,490 |
| Medication subtotal | $3,888 | $3,888 |
| Clinical access fee | per visit, $39 message or $59 video | monthly subscription, $39 or $119, unresolved |
| Access fee over 12 months | $176 on a model of one video visit plus three message visits | $468 at $39 a month, or $1,428 at $119 a month |
| Modelled first-year total | about $4,064 | $4,356 to $5,316 |
Three honest caveats sit on that table. The visit count is a modelling assumption, not a published package, and a patient needing monthly contact would close most of the gap against a $39 subscription, because twelve message visits at $39 each come to $468 exactly. The GoodRx subscription figure is genuinely unresolved, and the swing between $39 and $119 a month is $960 a year, which is larger than every other difference in the comparison combined. And the dose path assumes the patient reaches and stays on the 2.4 mg maintenance dose, which is the gap our piece on what $25 for the first month actually costs over a year was written to measure.
There is also a route that beats both and belongs in any honest answer. Insured patients were quoted as low as $25 per month by Amazon, and Novo's insured savings programme was reported at $0 for Wegovy and $25 for Ozempic in November 2025. If your plan covers the drug, the comparison that matters is your own copay against these cash prices, not Amazon against GoodRx. Eligible Medicare patients are quoted $50 a month at Amazon, which no cash route here approaches.
Does the GoodRx markup pattern carry over to Amazon?
No, and the more useful finding is that the pattern no longer describes GoodRx on these drugs either. Our earlier piece on why GoodRx costs more than buying Wegovy direct documented coupon prices for the injectable pen sitting close to list, around $1,229 to $1,419 with a median near $1,319, against a direct price of $349, a multiple of roughly 3.8. That piece flagged its own coupon range as coming from a commercial price blog rather than a primary source, and that caveat still stands.
The mechanism behind the old pattern was specific. A discount card can only discount a price competition has already pushed down, which is why KFF finds the deep savings on generics, where about 90 per cent of United States prescriptions were filled in 2024 and about three-quarters of drugs with generic equivalents came out cheaper via GoodRx or an online pharmacy than via brand coupons. A single-source brand injectable left a coupon almost nothing to cut.
What changed is not GoodRx's skill at negotiating. It is that the manufacturers started publishing low cash prices and recruiting every channel they could to display them, GoodRx and Amazon included. When both routes are quoting the same manufacturer number, the question of which marks it up has no answer, because neither is marking it up. That also means the old near-list coupon price has not necessarily vanished for everyone, and anyone who fails the self-pay programme's eligibility test may still meet a price closer to the retail rate, which this article could not test because the live page was blocked.
For comparison, the pattern across the wider market is covered in our audits of NovoCare versus Ro over a full year and LillyDirect versus Hims over a full year, where the same structure appears. The medication price converges and the wrapper is where the money moves.
Where is each route genuinely different?
In logistics, eligibility support, and what happens when something goes wrong, not in the price of the drug. These are real differences and they are the ones worth choosing on.
- Amazon delivers to all 50 states with same-day delivery in nearly 3,100 cities as of September 2026, and Pharmaceutical Commerce reported on 12 January 2026 that the Wegovy pill would also roll out to Amazon Pharmacy kiosks for in-person pickup.
- GoodRx works across more than 70,000 pharmacies, which means you collect at a counter you already use rather than waiting on a delivery.
- Amazon's on-demand care tier explicitly excludes prior-authorisation support, which matters if you intend to pursue insurance coverage rather than pay cash.
- GoodRx's subscription was reported to include unlimited messaging with a provider, which changes the arithmetic for anyone expecting frequent contact.
- Both require a valid prescription from a licensed clinician, and both require an eligibility assessment for the manufacturer self-pay price. Neither is a way around a prescriber.
How strong is the evidence behind each claim here?
Mixed, and two of the claims a reader is most likely to want are the weakest in the article. The table marks each one rather than letting the strong findings carry the weak ones.
| Claim | Evidence type | Strength |
|---|---|---|
| Both routes quote the manufacturer's cash price for the Wegovy pill | GoodRx's own release title, clinical trade journal, business press, plus live manufacturer page | Strong, four independent sources agree |
| Current NovoCare self-pay ladder for Wegovy pill and pen | manufacturer price page, retrieved live in session | Strong for the price, primary for its own commercial terms |
| Amazon's published cash floors of $149 oral and $199 injectable | Amazon's own programme page, retrieved live | Strong for the floors, silent on per-dose prices |
| Neither company negotiates its own GLP-1 price | manufacturer release stating it sets the cost, KFF noting most coupons are also manufacturer prices, identical ladders | Moderate to strong, but an inference, no company says it in these words |
| Amazon per-dose price for Wegovy injection and Zepbound | none obtainable, sign-in and prescription wall, GLP-1 paths returned 404 | Unverified, the $349 and $399 figures are carried over from NovoCare |
| GoodRx live coupon price today | none obtainable, HTTP 403 and a human-verification wall | Unverified, all GoodRx figures here are dated announcements |
| Current GoodRx subscription fee | company release at $39 in November 2025, trade journal reporting a rise to $119 on 1 February 2026, only non-primary blogs assert $39 today | Weak and conflicting, the single largest uncertainty in the annual model |
| Zepbound self-pay ladder at $299, $399 and $449 | trade publications, Lilly's own investor pages returned 403 or timed out on every attempt | Moderate, primary source not reached in session |
| Modelled first-year totals | arithmetic on the prices above plus an assumed visit count and dose path | Weak as a personal forecast, useful only as a structure |
| Wegovy injection list price | business press rounding it to roughly $1,000 per month in January 2026, against about $1,349 used in our earlier piece | Weak, the sources disagree and neither is a manufacturer list-price disclosure |
What could change these numbers?
A dated reset is already on the calendar, and it affects the better of the two prices in the model above. NovoCare's live page states that the $199 introductory price is a limited-time offer with pricing to be updated after 31 December 2026. The original end date for that offer, as reported in November 2025, was 31 March 2026, so it has already been extended once, which is a reason to treat the next date as a planning assumption rather than a certainty. Our piece on the 31 December 2026 reset across GLP-1 price routes tracks what expires when.
The oral ladder has already stepped once in the way these programmes tend to, with the 4 mg dose moving from $149 to $199 after 15 April 2026, which we covered in the 4 mg price rise from $149 to $199. CNBC also reported on 5 January 2026 that the starting dose of the pill would be available at $149 per month on TrumpRx under a deal Novo Nordisk struck with the administration in November, which adds a third channel quoting the same manufacturer figure. The direction of travel is that the number of places showing a given GLP-1 cash price keeps growing while the price itself stays a manufacturer decision.
Frequently asked questions
Is Amazon Pharmacy cheaper than GoodRx for Wegovy?
Not on the medication, because on the evidence available on 15 October 2026 both quote the same manufacturer self-pay price. On the access fee, Amazon's per-visit model at $39 or $59 a visit came out cheaper than a twelve-month subscription in the model above, by roughly $292 against a $39 monthly fee and roughly $1,252 against a $119 monthly fee. Those gaps depend on how many visits you actually need.
Can I see Amazon Pharmacy's GLP-1 price if I do not have a prescription?
Not the per-dose price. Amazon publishes floors of $149 for oral and $199 for injectable cash-pay on its programme page, but its pharmacy pages showed no drug price to a signed-out visitor when checked on 15 October 2026. The price appears at checkout after sign-in against a prescription on file.
Does GoodRx still show prices close to list for the Wegovy injection?
This article could not test it, because goodrx.com returned HTTP 403 and a human-verification wall on every attempt in this session. The possibility is live rather than closed, since the manufacturer self-pay price carries an eligibility assessment, and anyone who does not qualify may see a different number. Treat any figure you are shown as applying to your own eligibility, on the date you see it.
Which route is cheapest if I have insurance?
Probably neither cash route. Amazon quotes insured patients as low as $25 per month, Novo's insured savings programme was reported at $0 for Wegovy in November 2025, and eligible Medicare patients are quoted $50 a month at Amazon. Copays and deductibles vary by plan, so the only comparison that settles it is your own plan's quote against the cash prices above.
Why did Amazon's injectable floor change from $299 to $199?
Because the floor tracks whichever manufacturer offer is currently lowest. Pharmaceutical Executive recorded $299 at the April 2026 programme launch, and Amazon's page dated 15 September 2026 shows $199, which is Novo Nordisk's introductory price for the first two months on the Wegovy pen. A starting price is the cheapest thing on the shelf that month, not the price you will pay in month three.
Do either of these routes let me skip getting a prescription?
No. Both require a valid prescription from a licensed clinician, and the manufacturer self-pay prices additionally require an eligibility assessment. GoodRx's process was described as meeting a licensed health care provider, completing an eligibility assessment, and receiving a prescription. Amazon routes through One Medical clinicians or accepts a prescription sent by your own prescriber.
Sources
- NovoCare, Wegovy self-pay pricing page, retrieved live 15 October 2026. Manufacturer price page, primary for its own commercial terms.
- Amazon, One Medical GLP-1 management programme announcement, published 21 April 2026 and updated 15 September 2026, retrieved 15 October 2026. Company announcement, primary for its own prices, not independent.
- Amazon Pharmacy home page, retrieved 15 October 2026. Checked for public drug pricing and found none for signed-out visitors.
- Novo Nordisk, press release on telehealth collaborations through NovoCare Pharmacy, 29 April 2025. Manufacturer release stating that Novo Nordisk sets the cash price.
- KFF, TrumpRx: What's the Value for Customers?, 24 February 2026. Independent health policy research, used for the channel-overlap finding and the generics comparison.
- CNBC, Novo Nordisk cuts direct-to-consumer prices for Wegovy and Ozempic to $349 a month, 17 November 2025. Business press reporting the manufacturer announcement.
- CNBC, First GLP-1 pill for obesity from Novo Nordisk launches in the US, 5 January 2026. Used for the $149 to $299 oral ladder, the channel list, the TrumpRx price and the list-price figure.
- The American Journal of Managed Care, GoodRx to Match Novo Nordisk Price for Oral Semaglutide, 5 January 2026. Clinical trade journal, used for the matching language, the dose ladder, the eligibility steps and the subscription fee conflict.
- The American Journal of Managed Care, FDA Approves Monthly KwikPen Option for Tirzepatide, 23 February 2026. Used for the KwikPen approval and the $299 starting self-pay price.
- GoodRx, GoodRx Now Offers Novo Nordisk's Cash Price for the Launch of the Wegovy Pill, 5 January 2026. Company release. The body could not be retrieved in session, so only the title, date and search-indexed summary are relied on.
- GoodRx, $39 per month weight-loss telemedicine subscription and $199 introductory cash price for Ozempic and Wegovy, 17 November 2025. Company release. Body returned HTTP 403 in session, title and date only.
- Pharmaceutical Commerce, Novo Nordisk rolls out $199 intro offer for Wegovy and Ozempic, 18 November 2025. Trade publication, used for the channel list carrying the introductory offer.
- Pharmaceutical Commerce, GoodRx and Eli Lilly partner to expand access to Foundayo and Zepbound KwikPen, 9 April 2026. Trade publication, not primary.
- Pharmaceutical Commerce, Amazon Pharmacy adds FDA-approved Wegovy pill, 12 January 2026. Trade publication, used for delivery reach and the kiosk rollout.
- Pharmaceutical Executive, Amazon One Medical launches GLP-1 management programme, 22 April 2026. Trade publication, used for the April 2026 floors and visit fees that have since changed.
- Pharmaceutical Executive, Lilly reduces price of Zepbound single-dose vials for self-pay patients, 1 December 2025. Trade publication, used for the $299, $399 and $449 Zepbound ladder.
- Pharmaceutical Executive, Lilly launches full Zepbound dose access through LillyDirect self-pay, 16 June 2025. Trade publication, used only to date the earlier $349 and $499 vial prices now superseded.
Eli Lilly's own investor news releases were attempted repeatedly at investor.lilly.com and lilly.gcs-web.com, including the PDF and static-file paths, and every request returned HTTP 403 or timed out. The GoodRx consumer site returned HTTP 403 and a human-verification challenge. Every Lilly price and every GoodRx price in this article therefore rests on a company release title or a trade publication rather than on a primary page opened in session, and the scoring table above marks that limitation against each affected claim.